Dexcom, a provider in real-time continuous glucose monitoring for people with diabetes, announced the FDA has cleared its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all types of diabetes.
With Dexcom G7, the CGM solution now offers a more powerful and easier to use system with a small, all-in-one wearable, completely redesigned mobile app, and no fingersticks1 or scanning required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels and help users spend more time in range.2,3
The system features a predictive low alert that provides a 20-minute advance warning of potentially dangerous low glucose levels so users can act quickly to avoid a hypoglycemic event. This critical feature continues to be at the forefront of the Dexcom experience, with more than 52 million Urgent Low Soon alerts acknowledged—more than 11 million of those in the middle of the night.4Users can also share information with anyone, anytime through remote monitoring and reporting capabilities.5 These features, among others, helped Dexcom G7 earn recognition as a CES 2023 innovation awards honoree in the wearable technology, digital health category.
Dexcom says it is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.
“The first thing that stood out to me when I started using the Dexcom CGM was how easy it was to use,” says Zac Harmon, a Dexcom Warrior and blues musician. “It’s small, non-intrusive and has been the biggest part of my diabetes journey. It feels like it was made just for me, so I can focus more on what’s really important in my life.”
As diabetes becomes increasingly prevalent, it’s more important than ever for all people with diabetes to have access to the best care and technology.
“Dexcom G7 is so simple and easy to use that it should be prescribed to every person with Type 1 and Type 2 diabetes,” says Thomas Grace, MD, a primary care physician in Findlay, Ohio. “G7 isn’t just great for people with diabetes, it’s great for healthcare professionals as well. The integration of Dexcom Clarity into the mobile app provides easy access to retrospective insights about a patient’s glycemic management during in person or telehealth appointments. With its exceptional accuracy and ease of use, I’m confident G7 will be a game changer for my patients.”
Dexcom expects to initiate a U.S. launch of Dexcom G7 in early 2023. To facilitate immediate access to G7 for as many users as possible, the company will have accessible cash pay options in place as the company transitions coverage availability for G7.
“There’s a reason Dexcom has the best-selling real-time CGM on the market,” says Kevin Sayer, chairman, president, and CEO of Dexcom. “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability, and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.”
1 If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
2 Results obtained with a prior generation Dexcom CGM System.
3 Beck RW, et al. JAMA. 2017;317(4):371-378.
4 Dexcom, data on file, 2022.
5 Separate Dexcom Follow app and internet connection required. Internet connectivity required for data sharing. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions.
Featured image: Dexcom G7 builds on the performance of Dexcom Continuous Glucose Monitoring, which lowers A1C, reduces hyper- and hypoglycemia, and increases time in range. Photo: Dexcom